REGENXBIO (RGNX) Competitors $8.93 -0.08 (-0.89%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$8.95 +0.02 (+0.22%) As of 08/29/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RGNX vs. DYN, APGE, TWST, BEAM, CDTX, IMCR, BHVN, WVE, AUPH, and TVTXShould you be buying REGENXBIO stock or one of its competitors? The main competitors of REGENXBIO include Dyne Therapeutics (DYN), Apogee Therapeutics (APGE), Twist Bioscience (TWST), Beam Therapeutics (BEAM), Cidara Therapeutics (CDTX), Immunocore (IMCR), Biohaven (BHVN), WAVE Life Sciences (WVE), Aurinia Pharmaceuticals (AUPH), and Travere Therapeutics (TVTX). These companies are all part of the "pharmaceutical products" industry. REGENXBIO vs. Its Competitors Dyne Therapeutics Apogee Therapeutics Twist Bioscience Beam Therapeutics Cidara Therapeutics Immunocore Biohaven WAVE Life Sciences Aurinia Pharmaceuticals Travere Therapeutics REGENXBIO (NASDAQ:RGNX) and Dyne Therapeutics (NASDAQ:DYN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings. Is RGNX or DYN more profitable? Dyne Therapeutics has a net margin of 0.00% compared to REGENXBIO's net margin of -112.70%. Dyne Therapeutics' return on equity of -64.12% beat REGENXBIO's return on equity.Company Net Margins Return on Equity Return on Assets REGENXBIO-112.70% -66.95% -34.14% Dyne Therapeutics N/A -64.12%-56.75% Do institutionals and insiders hold more shares of RGNX or DYN? 88.1% of REGENXBIO shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 12.8% of REGENXBIO shares are owned by insiders. Comparatively, 14.1% of Dyne Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more volatility & risk, RGNX or DYN? REGENXBIO has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Does the media favor RGNX or DYN? In the previous week, Dyne Therapeutics had 10 more articles in the media than REGENXBIO. MarketBeat recorded 16 mentions for Dyne Therapeutics and 6 mentions for REGENXBIO. Dyne Therapeutics' average media sentiment score of 1.23 beat REGENXBIO's score of 1.22 indicating that Dyne Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment REGENXBIO 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dyne Therapeutics 9 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate RGNX or DYN? REGENXBIO presently has a consensus target price of $28.38, suggesting a potential upside of 217.75%. Dyne Therapeutics has a consensus target price of $34.07, suggesting a potential upside of 152.53%. Given REGENXBIO's higher possible upside, equities research analysts plainly believe REGENXBIO is more favorable than Dyne Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score REGENXBIO 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Dyne Therapeutics 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 3 Strong Buy rating(s) 3.06 Which has preferable earnings and valuation, RGNX or DYN? REGENXBIO has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioREGENXBIO$83.33M5.41-$227.10M-$3.44-2.60Dyne TherapeuticsN/AN/A-$317.42M-$3.86-3.49 SummaryDyne Therapeutics beats REGENXBIO on 9 of the 16 factors compared between the two stocks. Get REGENXBIO News Delivered to You Automatically Sign up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RGNX vs. The Competition Export to ExcelMetricREGENXBIOMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$451.09M$3.09B$5.72B$9.78BDividend YieldN/A2.28%4.10%4.03%P/E Ratio-2.6020.7883.2726.59Price / Sales5.41392.10536.23111.53Price / CashN/A44.2237.4459.26Price / Book2.118.0710.556.58Net Income-$227.10M-$53.98M$3.27B$265.95M7 Day Performance-0.89%-0.88%0.40%0.17%1 Month Performance4.94%7.72%7.31%3.90%1 Year Performance-26.92%7.03%46.58%19.67% REGENXBIO Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RGNXREGENXBIO4.3415 of 5 stars$8.93-0.9%$28.38+217.7%-26.9%$451.09M$83.33M-2.60370Positive NewsDYNDyne Therapeutics3.5154 of 5 stars$13.00+3.3%$34.07+162.1%-70.7%$1.79BN/A-3.37100Positive NewsAPGEApogee Therapeutics3.7691 of 5 stars$36.94-3.5%$99.00+168.0%-28.9%$1.76BN/A-8.9491News CoveragePositive NewsAnalyst ForecastTWSTTwist Bioscience3.9006 of 5 stars$27.39-4.2%$49.40+80.4%-37.6%$1.73B$312.97M-18.89990Positive NewsBEAMBeam Therapeutics2.2232 of 5 stars$16.44-1.2%$48.45+194.7%-38.7%$1.68B$60.27M-3.65510Positive NewsCDTXCidara Therapeutics3.5152 of 5 stars$64.13-3.4%$64.14+0.0%+450.0%$1.68B$1.27M-5.7690Positive NewsIMCRImmunocore1.5199 of 5 stars$32.59-1.0%$56.89+74.6%-10.2%$1.66B$310.20M-81.48320Positive NewsBHVNBiohaven3.7404 of 5 stars$14.96-4.2%$54.23+262.5%-61.1%$1.65BN/A-1.95239WVEWAVE Life Sciences4.7405 of 5 stars$9.94-2.1%$20.27+103.9%+67.2%$1.62B$108.30M-11.04240News CoveragePositive NewsInsider TradeAUPHAurinia Pharmaceuticals2.9724 of 5 stars$12.14-1.1%$12.00-1.2%+76.1%$1.62B$235.13M28.23300Positive NewsTVTXTravere Therapeutics2.3091 of 5 stars$17.23-3.9%$32.21+87.0%+84.8%$1.60B$233.18M-8.45460Positive NewsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies DYN Alternatives APGE Alternatives TWST Alternatives BEAM Alternatives CDTX Alternatives IMCR Alternatives BHVN Alternatives WVE Alternatives AUPH Alternatives TVTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RGNX) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding REGENXBIO Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share REGENXBIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
